David Hamrock, MD
Dermatology · Cleveland, OHNPI 1215990288
Payments from drug & device makers
Across 878 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Johnson & Johnson$3K
- Novartis$2K
- Lilly USA, LLC$1K
- Sun Pharmaceutical Industries Inc.$1K
- UCB, Inc.$940
- plus $6K from 33 others
What the payments were for
- Food & beverage$18,61396%
- Education$7544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 240 | $5,536 |
| Johnson & Johnson | 172 | $2,740 |
| Novartis | 66 | $1,545 |
| Lilly USA, LLC | 64 | $1,335 |
| Sun Pharmaceutical Industries Inc. | 37 | $1,074 |
| UCB, Inc. | 48 | $940 |
| Sanofi | 39 | $910 |
| LEO Pharma Inc. | 35 | $720 |
| Janssen Scientific Affairs, LLC | 7 | $716 |
| Regeneron Healthcare Solutions, Inc. | 29 | $612 |
| Mallinckrodt Hospital Products Inc. | 21 | $605 |
| Amgen | 25 | $503 |
| Mallinckrodt Enterprises LLC | 17 | $482 |
| E.r. Squibb & Sons, L.L.C. | 18 | $392 |
| Genentech USA, Inc. | 15 | $248 |
| Boehringer Ingelheim | 8 | $200 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Bristol Myers Squibb | 4 | $71 |
| Organogenesis Inc. | 3 | $65 |
| Pfizer | 1 | $64 |
| Incyte Corporation | 3 | $58 |
| Biocon Biologics Inc | 2 | $47 |
| Convatec Inc. | 2 | $41 |
| Galderma Laboratories, L.p. | 2 | $40 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $37 |
| Fresenius Kabi USA, LLC | 2 | $34 |
| Qiagen, LLC | 2 | $31 |
| Prugen, Inc. Pharmaceuticals | 2 | $24 |
| Mylan Institutional Inc. | 1 | $23 |
| Cipher Pharmaceuticals US LLC | 1 | $21 |
| Dermavant Sciences, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Dermira, Inc. | 1 | $17 |
| ETS Wound Care LLC | 1 | $17 |
| Sandoz | 1 | $16 |
| Merck | 1 | $15 |
| Botanix SB Inc | 1 | $14 |
| DUSA Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,366 in reported general payments places this provider in the 85th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 21 | $292,320 |
| SkyriziRisankizumab-Rzaa | 12 | $242,089 |
| Cosentyx Unoready PenSecukinumab | 16 | $164,442 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $79,869 |
| OtezlaApremilast | 13 | $64,341 |
| Dupixent SyringeDupilumab | 12 | $48,759 |
| Clobetasol Propionate | 78 | $3,542 |
| Fluorouracil | 32 | $2,789 |
| Fluocinonide | 81 | $2,534 |
| Dapsone | 19 | $1,914 |
| Metronidazole | 34 | $1,575 |
| Tretinoin | 12 | $1,319 |
| Ketoconazole | 95 | $1,169 |
| Hydroxychloroquine Sulfate | 13 | $653 |
| ValacyclovirValacyclovir Hcl | 26 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,740 | $292,32021 claims |
| AbbVieSkyrizi | $5,536 | $242,08912 claims |
| AmgenOtezla | $503 | $64,34113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 460 dermatology providers in Ohio.
Other dermatology in Cleveland
- Neil KormanCleveland$6M
- Anthony FernandezCleveland$1.4M
- Wilma BergfeldCleveland$642K
- Shilpi KhetarpalCleveland$383K
- Edward MaytinCleveland$190K
- Alex HirshCleveland$159K
- Mara Weinstein VelezCleveland$129K
- Samantha PollyCleveland$80K
- Matthew ZirwasBexley$7.4M
- Jeffrey TraversDayton$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.